Adial Pharmaceuticals Inc Cash Flow Conversion Efficiency
Adial Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Adial Pharmaceuticals Inc (ADIL) has a cash flow conversion efficiency ratio of -40.786x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.36 Million) by net assets ($156.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Adial Pharmaceuticals Inc (2015–2025)
Cash flow conversion efficiency of Adial Pharmaceuticals Inc from 2015 to 2025. This chart illustrates how Adial Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ADIL live share price for real-time trading data and today's change.
Adial Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Adial Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Adial Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adial Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Adial Pharmaceuticals Inc (ADIL) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
M.P.Evans Group
LSE:MPE
|
0.109x |
|
Rocket One Inc.
NASDAQ:RKTO
|
-0.733x |
|
Star Diamond Corp
TO:DIAM
|
-0.152x |
|
OHEIM INT Co.Ltd
KQ:309930
|
0.282x |
|
Eastern Technical Engineering Public Company Limited
BK:ETE
|
0.021x |
|
Pilulka Lekarny as
PR:PINK
|
N/A |
|
Admiralty Resources NL
AU:ADY
|
0.000x |
|
Four Leaf Acquisition Corporation Class A Common Stock
NASDAQ:FORL
|
-0.074x |
Annual Cash Flow Conversion Efficiency for Adial Pharmaceuticals Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Adial Pharmaceuticals Inc from 2015 to 2025. Review financial agility of Adial Pharmaceuticals Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.28 Million | $-6.49 Million | -1.230x | +27.69% |
| 2024-12-31 | $4.07 Million | $-6.92 Million | -1.702x | -2.08% |
| 2023-12-31 | $4.08 Million | $-6.81 Million | -1.667x | +51.17% |
| 2022-12-31 | $3.28 Million | $-11.19 Million | -3.414x | -0.22% |
| 2021-12-31 | $3.51 Million | $-11.95 Million | -3.407x | -77.89% |
| 2020-12-31 | $3.99 Million | $-7.63 Million | -1.915x | -115.72% |
| 2019-12-31 | $7.14 Million | $-6.34 Million | -0.888x | -57.80% |
| 2018-12-31 | $4.44 Million | $-2.50 Million | -0.563x | -213.40% |
| 2017-12-31 | $-997.55K | $-494.86K | 0.496x | -81.29% |
| 2016-12-31 | $-103.49K | $-274.38K | 2.651x | +192.97% |
| 2015-12-31 | $163.15K | $-465.22K | -2.852x | -- |
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid p… Read more